Literature DB >> 35013863

The effects of glipizide on DNA damage and nuclear transport in differentiated 3T3-L1 adipocytes.

Mehtap Cevik1, Selen Caker1, Gokce Deliorman2, Penbe Cagatay3, Meliha Koldemir Gunduz4, Belgin Susleyici5.   

Abstract

BACKGROUND: Despite commonly use for treatment of type II diabetes, possible effects of glipizide on nuclear transport and DNA damage in cells are unknown. Since clinical response of glipizide may change with aging, the aim of the study was to investigate the effect of glipizide by comparing mature and senescent adipocytes. METHODS AND
RESULTS: The effects of glipizide were investigated in 3T3-L1 adipocytes. Effective and lethal doses were determined by real-time monitoring iCELLigence system. Comet assay was performed to determine DNA damage and quantitative PCR was conducted to detect gene expression levels. RAN expressions were found to be up regulated in mature 180 µM glipizide treated adipocytes compared to control group (p < 0.05); whereas down regulated in senescent 180 µM glipizide treated adipocytes compared to their control adipocytes (p < 0.05). Olive Tail Moment values were significantly higher in mature 180 µM glipizide treated adipocytes (MTG) and senescent 180 µM glipizide treated adipocytes (STG) comparing their untreated controls (p < 0.001 and p < 0.001 respectively). Also class 5 comets that shows severe DNA damage were found to be higher in both MTG and STG groups than their controls (p < 0.001 and p < 0.001, respectively). OTM values were higher in STG than MTG (p < 0.001).
CONCLUSIONS: This is the first study that reports glipizide caused DNA damage increasing with senescence in adipocytes. As a response to glipizide treatment Ran gene expression increased in mature; and decreased in senescent adipocytes. Further studies are needed to reveal the effect of glipizide on DNA and nuclear interactions in molecular level.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  3T3-L1 adipocytes; DNA damage; Glipizide; Nuclear transport; RAN gene

Mesh:

Substances:

Year:  2022        PMID: 35013863     DOI: 10.1007/s11033-021-06942-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  43 in total

1.  Antioxidant status in experimental type 2 diabetes mellitus: effects of glibenclamide and glipizide on various rat tissues.

Authors:  S Tüzün; F K Girgin; E Y Sözmen; G Menteş; B Ersöz
Journal:  Exp Toxicol Pathol       Date:  1999-07

2.  Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells.

Authors:  A Sliwinska; J Blasiak; J Drzewoski
Journal:  Chem Biol Interact       Date:  2006-07-27       Impact factor: 5.192

Review 3.  Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Authors:  Andrew J Krentz; Clifford J Bailey
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Increased frequency of micronuclei in diabetes mellitus patients using pioglitazone and glimepiride in combination.

Authors:  Noor Ahmad Shaik; Jilani Purusottapatnam Shaik; Sharique Ali; Ahamad Imran; Durga Koteswara Rao
Journal:  Food Chem Toxicol       Date:  2010-09-22       Impact factor: 6.023

5.  Inhibitory effect of glimepiride on nicotinamide-streptozotocin induced nuclear damages and sperm abnormality in diabetic Wistar rats.

Authors:  Syed Imam Rabbani; Kshama Devi; Salma Khanam
Journal:  Indian J Exp Biol       Date:  2009-10       Impact factor: 0.818

Review 6.  Oral pharmacologic management of type 2 diabetes.

Authors:  M C Riddle
Journal:  Am Fam Physician       Date:  1999-12       Impact factor: 3.292

Review 7.  Pharmacokinetic optimisation of oral hypoglycaemic therapy.

Authors:  P Marchetti; R Giannarelli; A di Carlo; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

8.  In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM).

Authors:  Agnieszka Sliwinska; Janusz Blasiak; Jacek Kasznicki; Jozef Drzewoski
Journal:  Chem Biol Interact       Date:  2008-04-08       Impact factor: 5.192

Review 9.  Type 2 diabetes and oral antihyperglycemic drugs.

Authors:  Cassia S Mizuno; Amar G Chittiboyina; Theodore W Kurtz; Harrihar A Pershadsingh; Mitchell A Avery
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

10.  Assessment of in vivo and in vitro genotoxicity of glibenclamide in eukaryotic cells.

Authors:  Juliane Rocha de Sant'Anna; Claudinéia Conationi da Silva Franco; Paulo Cezar de Freitas Mathias; Marialba Avezum Alves de Castro-Prado
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.